Cargando…

Management of Recurrent Endometrial Cancer or Atypical Endometrial Hyperplasia Patients After Primary Fertility-Sparing Therapy

OBJECTIVE: To evaluate the efficacy and prognosis of fertility-sparing re-treatment on patients with recurrent endometrial cancer (EC) and atypical endometrial hyperplasia (AEH) who wish to preserve their uterus after complete remission (CR) for primary conservative therapy. METHODS: We performed a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Junyu, Cao, Dongyan, Yang, Jiaxin, Yu, Mei, Zhou, Huimei, Cheng, Ninghai, Wang, Jinhui, Zhang, Ying, Peng, Peng, Shen, Keng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458864/ https://www.ncbi.nlm.nih.gov/pubmed/34568074 http://dx.doi.org/10.3389/fonc.2021.738370

Ejemplares similares

Fertility-Sparing Treatment for Endometrial Cancer or Atypical Endometrial Hyperplasia Patients With Obesity
por: Chen, Junyu, et al.
Publicado: (2022)

Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia
por: Chen, Junyu, et al.
Publicado: (2022)

Prognosis of patients with endometrial cancer or atypical endometrial hyperplasia after complete remission with fertility-sparing therapy
por: Ga, Hiromi, et al.
Publicado: (2023)

Effect and Management of Excess Weight in the Context of Fertility-Sparing Treatments in Patients With Atypical Endometrial Hyperplasia and Endometrial Cancer: Eight-Year Experience of 227 Cases
por: Shan, Ying, et al.
Publicado: (2021)

Analysis of Factors Associated With Recurrence of Early-Stage Endometrial Carcinoma and Atypical Endometrial Hyperplasia in Infertile Women After In Vitro Fertilization Treatment
por: Guo, Yaxing, et al.
Publicado: (2022)

Fertility-sparing surgery for patients with low-grade endometrial stromal sarcoma
por: Xie, Weimin, et al.
Publicado: (2016)

Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review
por: Murakami, Isao, et al.
Publicado: (2023)

Fertility-Sparing Approaches in Atypical Endometrial Hyperplasia and Endometrial Cancer Patients: Current Evidence and Future Directions
por: Contreras, Nayanar-Adela, et al.
Publicado: (2022)

Survival outcomes and the prognostic significance of clinicopathological features in patients with endometrial clear cell carcinoma: a 35-year single-center retrospective study
por: Ma, Xiao, et al.
Publicado: (2023)

Fertility-Sparing Treatment in Young Patients With Grade 2 Presumed Stage IA Endometrioid Endometrial Adenocarcinoma
por: Yu, Mei, et al.
Publicado: (2020)

Clinical implications of morular metaplasia in fertility-preserving treatment for atypical endometrial hyperplasia and early endometrial carcinoma patients
por: Wu, Pengfei, et al.
Publicado: (2022)

Insulin Resistance and Metabolic Syndrome Increase the Risk of Relapse For Fertility Preserving Treatment in Atypical Endometrial Hyperplasia and Early Endometrial Cancer Patients
por: Li, Xingchen, et al.
Publicado: (2021)

Use of clinicopathological factors to predict prognosis of fertility-sparing treatment for endometrial endometrioid carcinoma and atypical hyperplasia
por: Zhang, Xiaobo, et al.
Publicado: (2022)

Insulin resistance and overweight prolonged fertility-sparing treatment duration in endometrial atypical hyperplasia patients
por: Yang, Bingyi, et al.
Publicado: (2018)

Fertility-Sparing Treatment in Young Women with Atypical Endometrial Hyperplasia and Low-Grade Endometrial Cancer: A Tertiary Center Experience
por: Shikeli, Sumaya, et al.
Publicado: (2020)

Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients
por: Mitsuhashi, Akira, et al.
Publicado: (2019)

Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial)
por: Mitsuhashi, Akira, et al.
Publicado: (2020)

Oncological and Reproductive Outcomes After Fertility-Sparing Surgery for Stage I Mucinous Ovarian Carcinoma
por: Lin, Wei, et al.
Publicado: (2022)

miRNAs as Candidate Biomarker for the Accurate Detection of Atypical Endometrial Hyperplasia/Endometrial Intraepithelial Neoplasia
por: Giglio, Simona, et al.
Publicado: (2019)

Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia
por: Fan, Yuan, et al.
Publicado: (2021)

Fertility-sparing treatment for endometrial cancer and atypical endometrial hyperplasia in patients with Lynch Syndrome: Molecular diagnosis after immunohistochemistry of MMR proteins
por: Catena, Ursula, et al.
Publicado: (2022)

Metabolic syndrome is an independent risk factor for time to complete remission of fertility-sparing treatment in atypical endometrial hyperplasia and early endometrial carcinoma patients
por: Ding, Yingqiao, et al.
Publicado: (2022)

Effects of Weight Status and Related Metabolic Disorders on Fertility-Sparing Treatment Outcomes in Endometrial Atypical Hyperplasia and Endometrial Cancer: A Retrospective Study
por: Liu, Sijia, et al.
Publicado: (2022)

Significance of serum and pathological biomarkers in fertility-sparing treatment for endometrial cancer or atypical hyperplasia: a retrospective cohort study
por: Wang, Yiqin, et al.
Publicado: (2021)

Clinical and Expression Significance of AKT1 by Co-expression Network Analysis in Endometrial Cancer
por: Huo, Xiao, et al.
Publicado: (2019)

Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia
por: Zhang, Qing, et al.
Publicado: (2017)

A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer
por: Zhang, Zhibo, et al.
Publicado: (2019)

Multimodal MRI-Based Radiomics-Clinical Model for Preoperatively Differentiating Concurrent Endometrial Carcinoma From Atypical Endometrial Hyperplasia
por: Zhang, Jieying, et al.
Publicado: (2022)

The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer
por: Guan, Jun, et al.
Publicado: (2022)

Maintenance Therapy Can Improve the Oncologic Prognosis and Obstetrical Outcome of Patients With Atypical Endometrial Hyperplasia and Endometrial Cancer After Fertility-Preserving Treatment: A Multicenter Retrospective Study
por: He, Yijiao, et al.
Publicado: (2021)

Hysteroscopic Curettage Followed by Megestrol Acetate Plus Metformin as a Fertility-Sparing Treatment for Women with Atypical Endometrial Hyperplasia or Well-Differentiated Endometrioid Endometrial Carcinoma
por: Jing, Chu-Yu, et al.
Publicado: (2022)

Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan: a survey by the Gynecologic Oncology Committee of the Japan Society of Obstetrics and Gynecology
por: Ushijima, Kimio, et al.
Publicado: (2023)

Oncological outcomes in fertility-sparing treatment in stage IA-G2 endometrial cancer
por: Ronsini, Carlo, et al.
Publicado: (2022)

Endometrial hyperplasia as a risk factor of endometrial cancer
por: Nees, Lisa K., et al.
Publicado: (2022)

Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: A meta-analysis and systematic review
por: Wei, Jing, et al.
Publicado: (2017)

Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment
por: Zhou, Shuang, et al.
Publicado: (2021)

Urine metabolomics for assessing fertility-sparing treatment efficacy in endometrial cancer: a non-invasive approach using ultra-performance liquid chromatography mass spectrometry
por: Chen, Junyu, et al.
Publicado: (2023)

Identification of Somatic Mutations in Papanicolaou Smear DNA and Plasma Circulating Cell-Free DNA for Detection of Endometrial and Epithelial Ovarian Cancers: A Pilot Study
por: Jiang, Xuan, et al.
Publicado: (2020)

Fertility-Sparing Treatment and Assisted Reproductive Technology in Patients with Endometrial Carcinoma and Endometrial Hyperplasia: Pregnancy Outcomes after Embryo Transfer
por: Friedlander, Hilary, et al.
Publicado: (2023)

Identification of prognosis markers for endometrial cancer by integrated analysis of DNA methylation and RNA-Seq data
por: Huo, Xiao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u5qnhth9r6q0ml91andt9p6iuf